DFN 10
Alternative Names: DFN-10Latest Information Update: 25 Mar 2021
Price :
$50 *
At a glance
- Originator Promius Pharma
- Class Antimigraines
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Migraine
Most Recent Events
- 25 Mar 2021 No development reported - Phase-II for Migraine (unspecified route)
- 01 Jan 2019 Phase-II clinical trials in Migraine before January 2019 (Promius Pharma pipeline, January 2019)